- Home
- IMNN vs SNTI Comparison
IMNN vs SNTI Comparison
Compare IMNN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- SNTI
- Stock Information
- Founded
- IMNN 1982
- SNTI 2016
- Country
- IMNN United States
- SNTI United States
- Employees
- IMNN N/A
- SNTI N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- SNTI Health Care
- Exchange
- IMNN Nasdaq
- SNTI Nasdaq
- Market Cap
- IMNN 14.7M
- SNTI 14.1M
- IPO Year
- IMNN 1985
- SNTI N/A
- Fundamental
- Price
- IMNN $1.03
- SNTI $2.12
- Analyst Decision
- IMNN Strong Buy
- SNTI
- Analyst Count
- IMNN 2
- SNTI 0
- Target Price
- IMNN $21.50
- SNTI N/A
- AVG Volume (30 Days)
- IMNN 227.1K
- SNTI 24.1K
- Earning Date
- IMNN 11-12-2024
- SNTI 11-11-2024
- Dividend Yield
- IMNN N/A
- SNTI N/A
- EPS Growth
- IMNN N/A
- SNTI N/A
- EPS
- IMNN N/A
- SNTI N/A
- Revenue
- IMNN N/A
- SNTI $338,000.00
- Revenue This Year
- IMNN N/A
- SNTI $254.47
- Revenue Next Year
- IMNN N/A
- SNTI $169.66
- P/E Ratio
- IMNN N/A
- SNTI N/A
- Revenue Growth
- IMNN N/A
- SNTI N/A
- 52 Week Low
- IMNN $0.48
- SNTI $1.52
- 52 Week High
- IMNN $3.65
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- IMNN 46.95
- SNTI 36.91
- Support Level
- IMNN $0.99
- SNTI $2.08
- Resistance Level
- IMNN $1.08
- SNTI $2.56
- Average True Range (ATR)
- IMNN 0.05
- SNTI 0.26
- MACD
- IMNN 0.00
- SNTI -0.04
- Stochastic Oscillator
- IMNN 44.44
- SNTI 14.12
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.